Affimed (AFMD) Competitors $1.19 +0.01 (+0.85%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AFMD vs. ENTA, ATOS, VXRT, CABA, NLTX, PLX, IFRX, SAVA, APLT, and ALGSShould you be buying Affimed stock or one of its competitors? The main competitors of Affimed include Enanta Pharmaceuticals (ENTA), Atossa Therapeutics (ATOS), Vaxart (VXRT), Cabaletta Bio (CABA), Neoleukin Therapeutics (NLTX), Protalix BioTherapeutics (PLX), InflaRx (IFRX), Cassava Sciences (SAVA), Applied Therapeutics (APLT), and Aligos Therapeutics (ALGS). These companies are all part of the "pharmaceutical products" industry. Affimed vs. Enanta Pharmaceuticals Atossa Therapeutics Vaxart Cabaletta Bio Neoleukin Therapeutics Protalix BioTherapeutics InflaRx Cassava Sciences Applied Therapeutics Aligos Therapeutics Enanta Pharmaceuticals (NASDAQ:ENTA) and Affimed (NASDAQ:AFMD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, community ranking, valuation, analyst recommendations, institutional ownership, earnings and risk. Does the media favor ENTA or AFMD? In the previous week, Affimed had 14 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 14 mentions for Affimed and 0 mentions for Enanta Pharmaceuticals. Affimed's average media sentiment score of 0.42 beat Enanta Pharmaceuticals' score of 0.33 indicating that Affimed is being referred to more favorably in the news media. Company Overall Sentiment Enanta Pharmaceuticals Neutral Affimed Neutral Is ENTA or AFMD more profitable? Enanta Pharmaceuticals has a net margin of -171.57% compared to Affimed's net margin of -7,836.26%. Enanta Pharmaceuticals' return on equity of -73.02% beat Affimed's return on equity.Company Net Margins Return on Equity Return on Assets Enanta Pharmaceuticals-171.57% -73.02% -28.70% Affimed -7,836.26%-193.84%-107.24% Do analysts recommend ENTA or AFMD? Enanta Pharmaceuticals presently has a consensus target price of $19.50, suggesting a potential upside of 210.51%. Affimed has a consensus target price of $13.50, suggesting a potential upside of 1,034.45%. Given Affimed's higher possible upside, analysts plainly believe Affimed is more favorable than Enanta Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enanta Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80Affimed 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has more volatility and risk, ENTA or AFMD? Enanta Pharmaceuticals has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Affimed has a beta of 2.06, meaning that its stock price is 106% more volatile than the S&P 500. Do institutionals & insiders hold more shares of ENTA or AFMD? 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 30.8% of Affimed shares are held by institutional investors. 13.6% of Enanta Pharmaceuticals shares are held by company insiders. Comparatively, 3.8% of Affimed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has better earnings and valuation, ENTA or AFMD? Affimed has lower revenue, but higher earnings than Enanta Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnanta Pharmaceuticals$67.64M1.97-$116.04M-$5.48-1.15Affimed$877K21.85-$114.66MN/AN/A Does the MarketBeat Community prefer ENTA or AFMD? Affimed received 122 more outperform votes than Enanta Pharmaceuticals when rated by MarketBeat users. Likewise, 70.24% of users gave Affimed an outperform vote while only 56.91% of users gave Enanta Pharmaceuticals an outperform vote. CompanyUnderperformOutperformEnanta PharmaceuticalsOutperform Votes31756.91% Underperform Votes24043.09% AffimedOutperform Votes43970.24% Underperform Votes18629.76% SummaryAffimed beats Enanta Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Ad Paradigm Press Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!Click here now for the urgent details. Get Affimed News Delivered to You Automatically Sign up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AFMD vs. The Competition Export to ExcelMetricAffimedPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.16M$6.57B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E RatioN/A10.4289.5817.17Price / Sales21.85195.801,116.12116.95Price / CashN/A57.1642.8237.86Price / Book0.285.094.774.78Net Income-$114.66M$151.83M$120.15M$225.60M7 Day Performance-44.65%-2.13%-1.92%-1.23%1 Month Performance-54.92%-3.10%11.47%3.36%1 Year Performance-73.85%11.54%30.54%16.60% Affimed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AFMDAffimed4.4532 of 5 stars$1.19+0.8%$13.50+1,034.5%-68.5%$19.16M$877,000.000.0076Analyst RevisionNews CoverageENTAEnanta Pharmaceuticals4.0505 of 5 stars$6.44+6.8%$19.50+202.8%-26.3%$136.49M$67.64M-1.10145ATOSAtossa Therapeutics1.5209 of 5 stars$1.08-3.6%$7.00+548.1%+32.4%$135.87MN/A-5.208VXRTVaxart1.5337 of 5 stars$0.59-0.5%$3.00+409.3%+2.8%$133.99M$20.14M-1.44109CABACabaletta Bio2.5472 of 5 stars$2.73-3.2%$26.25+861.5%-88.8%$133.43MN/A-1.3150Analyst DowngradeNews CoverageNLTXNeoleukin TherapeuticsN/A$13.96+1.5%N/A+532.5%$131.20MN/A-7.5690News CoveragePLXProtalix BioTherapeuticsN/A$1.78-1.4%N/A+2.9%$130.69M$65.49M-13.81200Gap DownIFRXInflaRx2.4077 of 5 stars$2.21-6.4%$8.00+262.0%+50.3%$130.13M$168,498.00-2.1960Analyst ForecastNews CoverageGap DownSAVACassava Sciences4.4021 of 5 stars$2.70-1.8%$111.50+4,029.6%-88.1%$129.90MN/A-1.9930News CoverageGap DownAPLTApplied Therapeutics4.5365 of 5 stars$1.11-3.5%$6.60+494.6%-70.3%$129.16M$9.99M-0.7130Analyst ForecastNews CoverageGap DownALGSAligos Therapeutics3.9844 of 5 stars$35.48+4.1%$75.00+111.4%+161.2%$127.30M$6.00M-2.5690News CoverageGap DownHigh Trading Volume Related Companies and Tools Related Companies ENTA Competitors ATOS Competitors VXRT Competitors CABA Competitors NLTX Competitors PLX Competitors IFRX Competitors SAVA Competitors APLT Competitors ALGS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AFMD) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Affimed Please log in to your account or sign up in order to add this asset to your watchlist. Share Affimed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AFMD Stock Alerts